Neural Regeneration Research,
Journal Year:
2023,
Volume and Issue:
20(4), P. 1092 - 1093
Published: Dec. 21, 2023
NeuroPhysiology
&
Behavior
Lab,
University
of
Castilla-La
Mancha,
Biomedical
Research
Center
(CRIB),
School
Medicine
Ciudad
Real,
Spain
*Correspondence
to:
Juan
D.
Navarro-López,
PhD,
[email
protected];
Lydia
Jiménez-Díaz,
protected].
This
is
an
open-access
article
distributed
under
the
terms
Creative
Commons
Attribution-Noncommercial-Share
Alike
4.0
Unported,
which
permits
unrestricted
use,
distribution,
and
reproduction
in
any
medium,
provided
original
work
properly
cited.
Signal Transduction and Targeted Therapy,
Journal Year:
2025,
Volume and Issue:
10(1)
Published: March 7, 2025
Redox
signaling
acts
as
a
critical
mediator
in
the
dynamic
interactions
between
organisms
and
their
external
environment,
profoundly
influencing
both
onset
progression
of
various
diseases.
Under
physiological
conditions,
oxidative
free
radicals
generated
by
mitochondrial
respiratory
chain,
endoplasmic
reticulum,
NADPH
oxidases
can
be
effectively
neutralized
NRF2-mediated
antioxidant
responses.
These
responses
elevate
synthesis
superoxide
dismutase
(SOD),
catalase,
well
key
molecules
like
nicotinamide
adenine
dinucleotide
phosphate
(NADPH)
glutathione
(GSH),
thereby
maintaining
cellular
redox
homeostasis.
Disruption
this
finely
tuned
equilibrium
is
closely
linked
to
pathogenesis
wide
range
Recent
advances
have
broadened
our
understanding
molecular
mechanisms
underpinning
dysregulation,
highlighting
pivotal
roles
genomic
instability,
epigenetic
modifications,
protein
degradation,
metabolic
reprogramming.
findings
provide
foundation
for
exploring
regulation
mechanistic
basis
improving
therapeutic
strategies.
While
antioxidant-based
therapies
shown
early
promise
conditions
where
stress
plays
primary
pathological
role,
efficacy
diseases
characterized
complex,
multifactorial
etiologies
remains
controversial.
A
deeper,
context-specific
signaling,
particularly
redox-sensitive
proteins,
designing
targeted
aimed
at
re-establishing
balance.
Emerging
small
molecule
inhibitors
that
target
specific
cysteine
residues
proteins
demonstrated
promising
preclinical
outcomes,
setting
stage
forthcoming
clinical
trials.
In
review,
we
summarize
current
intricate
relationship
disease
also
discuss
how
these
insights
leveraged
optimize
strategies
practice.
ACS Omega,
Journal Year:
2024,
Volume and Issue:
9(6), P. 6059 - 6073
Published: Feb. 5, 2024
Alzheimer's
disease
(AD)
is
a
neurodegenerative
disorder
characterized
by
progressive
and
irreversible
impairment
of
memory
other
cognitive
functions
the
aging
brain.
Pathways
such
as
amyloid
beta
neurotoxicity,
tau
pathogenesis
neuroinflammatory
have
been
used
to
understand
AD,
despite
not
knowing
definite
molecular
mechanism
which
causes
this
disease.
This
review
attempts
summarize
small
molecules
that
target
these
pathways
using
various
techniques
involving
high-throughput
screening,
modeling,
custom
bioassays,
spectroscopic
detection
tools.
Novel
evolving
screening
methods
developed
advance
drug
discovery
initiatives
in
AD
research
are
also
highlighted.
Nutrients,
Journal Year:
2024,
Volume and Issue:
16(9), P. 1288 - 1288
Published: April 26, 2024
The
abnormality
in
N6-methyladenosine
(m6A)
methylation
is
involved
the
course
of
Alzheimer’s
disease
(AD),
while
intervention
27-Hydroxycholesterol
(27-OHC)
can
affect
m6A
modification
brain
cortex.
Disordered
gut
microbiota
a
key
link
27-OHC
leading
to
cognitive
impairment,
and
further
studies
have
found
that
abundance
Roseburia
intestinalis
significantly
reduced
under
27-OHC.
This
study
aims
investigate
association
27-OHC,
gut,
learning
memory
ability
injury.
In
this
study,
9-month-old
male
C57BL/6J
mice
were
treated
with
antibiotic
cocktails
for
6
weeks
sweep
intestinal
flora,
followed
by
or
normal
saline
subcutaneous
injection,
then
gavage
applied
mouse.
level
brain,
barrier
function,
measured.
From
results,
we
observed
impairs
causing
disturbance
expression
methylation-related
enzymes
reducing
cortex,
finally
leads
impairment.
However,
supplementation
could
reverse
negative
effects
mentioned
above.
suggests
27-OHC-induced
impairment
might
be
linked
disturbance,
intestinalis,
as
probiotic
great
potential,
damage
caused
research
help
reveal
mechanism
neural
provide
important
scientific
evidence
future
use
neuroprotection.
Frontiers in Aging Neuroscience,
Journal Year:
2024,
Volume and Issue:
16
Published: Jan. 16, 2024
Background
Currently,
the
prevalence
of
Alzheimer’s
disease
(AD)
is
progressively
rising,
particularly
in
developed
nations.
There
an
escalating
focus
on
onset
and
progression
AD.
A
mounting
body
research
indicates
that
epigenetics
significantly
contributes
to
AD
holds
substantial
promise
as
a
novel
therapeutic
target
for
its
treatment.
Objective
The
objective
this
article
present
areas
interest,
comprehend
contextual
framework
subject
research,
investigate
prospective
direction
future
development.
Methods
ln
Web
Science
Core
Collection
(WOSCC),
we
searched
documents
by
specific
terms
their
corresponding
free
words.
VOSviewer,
CiteSpace
Scimago
Graphica
were
used
perform
statistical
analysis
measurement
metrics
such
number
published
papers,
national
cooperative
networks,
publishing
countries,
institutions,
authors,
co-cited
journals,
keywords,
visualize
networks
related
content
elements.
Results
We
selected
1,530
articles
from
WOSCC
January
2013
June
2023
about
Based
visual
analysis,
could
get
China
United
States
countries
with
most
field.
Bennett
DA
was
contributed
prestigious
scientist.
top
3
cited
journals
Journal
Disease,
Neurobiology
Aging
Molecular
Neurobiology.
According
keywords
frequency
citations,
ncRNAs,
transcription
factor,
genome,
histone
modification,
blood
DNA
methylation,
acetylation,
biomarkers
hot
directions
today.
Conclusion
bibliometric
epigenetic
promising
direction,
had
potential
be
targets.
Journal of Medicinal Chemistry,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 26, 2025
Alzheimer's
disease
(AD)
is
a
progressive
neurodegenerative
condition
marked
by
memory
loss
and
cognitive
decline.
With
current
treatments
offering
limited
effectiveness,
researchers
are
turning
to
natural
products
that
can
target
various
aspects
of
AD
pathology.
Clinically
approved
products,
such
as
galantamine
huperzine
A,
have
shown
success
in
treatments.
Furthermore,
compounds
epigallocatechin
gallate,
quercetin,
resveratrol
clinical
trials.
This
Perspective
examines
nearly
100
with
promising
neuroprotective
effects
preclinical
studies.
These
exhibit
diverse
pharmacological
actions
help
prevent
neurodegeneration
while
improving
functions.
Their
unique
structures
further
enhance
their
biological
activities,
making
them
candidates
for
drug
discovery.
stresses
the
importance
research
maximize
medical
benefits
these
highlights
potential
innovative
remedies
AD.
Continued
exploration
crucial
fully
leverage
capabilities
combating
